Pharmabiz33m
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours
EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...
Pharmabiz1h
Indian cancer centres adopting patient-reported outcomes to assess benefit-risk profile of therapies
Indian cancer care centres are now increasingly working to adopt patient-reported outcomes (PRO) to chip in a therapy’s benefit-risk assessment. This follows after a US FDA guidance on Core ...
Pharmabiz1h
Ayush Ministry to amend D&C Rules to regulate retail outlets of ASU drugs
Ayush Ministry to amend D&C Rules to regulate retail outlets of ASU drugs: Peethaambaran Kunnathoor, Chennai Monday, November 18, 2024, 08:00 Hrs [IST] The Union Ministry of Ayush ...
Pharmabiz1h
Nutraceuticals under drug regulation more beneficial; recommendations lack important aspects: Experts
Nutraceuticals under drug regulation more beneficial; recommendations lack important aspects: Experts: Gireesh Babu, New Delhi Monday, November 18, 2024, 08:00 Hrs [IST] Bringing ...
Pharmabiz1h
Pharmaceuticals exports report 8.21 per cent growth in October
Exports of drugs and pharmaceuticals from the country registered a growth of 8.21 per cent during the month of October this year, as compared to the same month of last year. Imports during the month ...
Pharmabiz2d
Dr. Nimmy VS of Vaidyaratnam Ayurveda College wins first prize in All India Ayurveda Thesis Competition 2024
Peethaambaran Kunnathoor, Chennai Saturday, November 16, 2024, 08:00 Hrs [IST] ...
Pharmabiz1d
Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions
Azurity Pharma gets US FDA approval for Danziten tablets, the first and only nilotinib with no mealtime restrictions: Woburn, Massachusetts Saturday, November 16, 2024, 17:00 Hrs ...
Pharmabiz2d
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma
EMA human medicine committee recommends approval of Sanofi’s Sarclisa to treat transplant-ineligible newly diagnosed multiple myeloma: Paris Saturday, November 16, 2024, 09:00 H ...
Pharmabiz1d
Biopharma & medical devices cos view advanced infrastructure to propel manufacturing & new drug development
Critical infrastructure in biopharma and medical devices plays a vital role in enabling innovation, bolstering research and development, and ensuring the production of novel drugs and products. It ...
Pharmabiz1d
WHO & US CDC new estimates show measles cases surge worldwide, infecting 10.3 million people in 2023
WHO & US CDC new estimates show measles cases surge worldwide, infecting 10.3 million people in 2023: Geneva Saturday, November 16, 2024, 10:00 Hrs [IST] Worldwide, there were an ...
Pharmabiz2d
Indian healthcare industry makes significant strides in epilepsy treatment with access to new drugs & surgical options
Nandita Vijayasimha, Bengaluru Saturday, November 16, 2024, 08:00 Hrs [IST] ...
Pharmabiz1d
Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836
Osivax announces first participant vaccinated in phase 2a clinical booster trial of influenza vaccine candidate OVX836: Lyon, France Saturday, November 16, 2024, 14:00 Hrs [IST] O ...